Schedule 13G ownership disclosure
Cullinan Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 230031106
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lynx1 Capital Management LP
Shares: 4,400,842.00 · Class: 7.5%
- Weston Nichols
Shares: 4,400,842.00 · Class: 7.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-003576
- Form type
- SCHEDULE 13G
- Filer
- Cullinan Therapeutics, Inc.
- CIK
- CIK 1789972
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership